$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000161521917000032 Filed on May 03, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$335.5K	$242.5K	$0.00
YoY Change	197.75%
Cost Of Revenue	$145.3K	$79.11K	$197.0K
YoY Change	31.0%	-59.85%
Gross Profit	$190.2K	$163.4K	-$197.0K
YoY Change	10743.67%	-182.96%
Gross Profit Margin	56.69%	67.39%
Selling, General & Admin	$4.990M	$4.590M	$5.110M
YoY Change	-7.25%	-10.18%	58.7%
% of Gross Profit	2623.58%	2808.35%
Research & Development	$4.076M	$3.915M	$4.387M
YoY Change	-33.12%	-10.76%	56.41%
% of Gross Profit	2143.15%	2395.34%
Depreciation & Amortization	$80.00K	$91.37K	$30.81K
YoY Change	33.33%	196.52%	229.23%
% of Gross Profit	42.06%	55.9%
Operating Expenses	$9.212M	$8.589M	$9.696M
YoY Change	-20.47%	-11.42%	61.03%
Operating Profit	-$8.877M	-$8.346M	-$9.696M
YoY Change	-22.61%	-13.92%	61.03%
Interest Expense	$70.00K	$80.00K	$100.0K
YoY Change	-36.36%	-20.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.800M	-$8.270M	-$9.696M
YoY Change	-23.28%	-14.71%	61.03%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.805M	-$8.268M	-$9.592M
YoY Change	-22.52%	-13.8%	59.41%
Net Earnings / Revenue	-2624.15%	-3408.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$12.75M	-$12.34M	-$15.22M
COMMON SHARES
Basic Shares Outstanding	17.97M shares	17.97M shares	17.95M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$47.10M	$52.80M	$84.40M
YoY Change	-37.12%	-37.44%	-23.62%
Cash & Equivalents	$39.25M	$21.20M	$54.00M
Short-Term Investments	$8.000M	$31.70M	$30.40M
Other Short-Term Assets	$1.200M	$1.600M	$2.000M
YoY Change	-47.83%	-20.0%	81.82%
Inventory	$688.2K	$414.3K	$112.6K
Prepaid Expenses
Receivables	$34.74K	$19.06K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$49.06M	$54.83M	$86.48M
YoY Change	-36.62%	-36.59%	-22.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$448.1K	$479.3K	$578.5K
YoY Change	-29.66%	-17.16%	453.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change
Other Assets	$0.00	$64.80K	$64.80K
YoY Change	-100.0%	0.0%	-23.94%
Total Long-Term Assets	$574.7K	$670.7K	$770.2K
YoY Change	-30.65%	-12.92%	110.05%
TOTAL ASSETS
Total Short-Term Assets	$49.06M	$54.83M	$86.48M
Total Long-Term Assets	$574.7K	$670.7K	$770.2K
Total Assets	$49.63M	$55.50M	$87.25M
YoY Change	-36.56%	-36.39%	-22.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.806M	$818.8K	$1.541M
YoY Change	16.93%	-46.88%	171.41%
Accrued Expenses	$3.100M	$2.300M	$1.500M
YoY Change	82.35%	53.33%	114.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.033M	$3.218M	$3.044M
YoY Change	48.16%	5.73%	114.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$100.0K	$15.44K
YoY Change		547.58%	-96.28%
Total Long-Term Liabilities	$100.0K	$100.0K	$15.44K
YoY Change		547.58%	-96.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.033M	$3.218M	$3.044M
Total Long-Term Liabilities	$100.0K	$100.0K	$15.44K
Total Liabilities	$5.125M	$3.278M	$3.082M
YoY Change	50.17%	6.34%	65.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.72M	-$84.91M	-$46.74M
YoY Change	61.28%	81.65%	233.22%
Common Stock	$1.729K	$1.703K	$1.601K
YoY Change	6.33%	6.37%	7.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.50M	$52.23M	$84.17M
YoY Change
Total Liabilities & Shareholders Equity	$49.63M	$55.50M	$87.25M
YoY Change	-36.56%	-36.39%	-22.06%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$8.805M	-$8.268M	-$9.592M
YoY Change	-22.52%	-13.8%	59.41%
Depreciation, Depletion And Amortization	$80.00K	$91.37K	$30.81K
YoY Change	33.33%	196.52%	229.23%
Cash From Operating Activities	-$5.690M	-$8.226M	-$9.174M
YoY Change	-39.01%	-10.33%	121.55%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$22.15K	$107.3K
YoY Change	-83.33%	-79.35%	306.46%
Acquisitions
YoY Change
Other Investing Activities	$23.78M	$6.900M	-$3.410M
YoY Change	-528.47%	-302.35%
Cash From Investing Activities	$23.74M	$6.881M	-$3.521M
YoY Change	-514.31%	-295.43%	13239.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00	$7.594K
YoY Change		-100.0%	-99.99%
NET CHANGE
Cash From Operating Activities	-5.690M	-$8.226M	-$9.174M
Cash From Investing Activities	23.74M	$6.881M	-$3.521M
Cash From Financing Activities	0.000	$0.00	$7.594K
Net Change In Cash	18.05M	-$1.344M	-$12.69M
YoY Change	-219.85%	-89.4%	-116.55%
FREE CASH FLOW
Cash From Operating Activities	-$5.690M	-$8.226M	-$9.174M
Capital Expenditures	-$30.00K	$22.15K	$107.3K
Free Cash Flow	-$5.660M	-$8.248M	-$9.281M
YoY Change	-38.14%	-11.13%	122.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17970590	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Flex Pharma, Inc.
CY2016Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2587573	USD
CY2017Q1	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2311405	USD
CY2016Q4	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	938665	USD
CY2017Q1	flks	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1385443	USD
CY2016Q1	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	106680	USD
CY2017Q1	flks	Property And Equipment Purchases In Accrued Expense PropertyAndEquipmentPurchasesInAccruedExpense	7100	USD
CY2017Q1	flks	Revenue Recognition Refund Period RevenueRecognitionRefundPeriod	P30D
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1192183	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	818794	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12181	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19062	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	42024	USD
CY2017Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	153859	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	153219	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	188414	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1614	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12353	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135962935	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137151662	USD
CY2016Q1	us-gaap	Advertising Expense AdvertisingExpense	0	USD
CY2017Q1	us-gaap	Advertising Expense AdvertisingExpense	665000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1518161	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1188752	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4299813	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3613410	shares
CY2016Q4	us-gaap	Assets Assets	63214979	USD
CY2017Q1	us-gaap	Assets Assets	55504530	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	62467269	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	54833869	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38658933	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	31743086	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2912	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4526	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12353	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	38660547	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31755439	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	16519620	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	27148418	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	6	security
CY2017Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	11	security
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	226309	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2015Q4	us-gaap	Cash Cash	66686695	USD
CY2016Q1	us-gaap	Cash Cash	53999629	USD
CY2016Q4	us-gaap	Cash Cash	22416040	USD
CY2017Q1	us-gaap	Cash Cash	21071684	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	52814770	USD
CY2016Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-12687066	USD
CY2017Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-1344356	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17970590	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17970590	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16773798	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17029249	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1678	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	1703	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9548202	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8279134	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	197020	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	79106	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21095	USD
CY2017Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	7579	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8398	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	59111	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	88344	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	80637	USD
CY2016Q1	us-gaap	Depreciation Depreciation	30813	USD
CY2017Q1	us-gaap	Depreciation Depreciation	91367	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1453665	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	583689	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M6D
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8626310	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5111695	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4594716	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	594639	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-366289	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6881	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-517446	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-276168	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	7781	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	37197	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7707	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	112569	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-39810	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	64800	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1083871	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	659732	USD
CY2016Q1	us-gaap	Interest Income Operating InterestIncomeOperating	103333	USD
CY2017Q1	us-gaap	Interest Income Operating InterestIncomeOperating	77854	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	454132	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	414322	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19888	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19628	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	434244	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	394694	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	185298	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	46129	USD
CY2017Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	2454	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3897593	USD
CY2017Q1	us-gaap	Liabilities Liabilities	3277526	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63214979	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55504530	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3889195	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3218415	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	38658933	USD
CY2017Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	31743086	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7594	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3521036	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6881236	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9173624	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8225592	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-9592461	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-8268395	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9592461	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8268395	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9695794	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	8588796	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9695794	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8346249	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64800	USD
CY2016Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	44259	USD
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-10739	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2255	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12013945	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9607422	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	107286	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22150	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	925983	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1585715	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8600195	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16510076	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	732	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7594	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	556315	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	479266	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4387079	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3914974	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	126595	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76645613	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84914008	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	240292	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	242547	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1518161	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1188752	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1128717	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.74
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71681	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	587500	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1605684	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1031433	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2156250	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2672069	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.66
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.68
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1031433	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2672069	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.68
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.93
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.58
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	740304	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M27D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M9D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M6D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M6D
CY2016Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	0	USD
CY2017Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	34000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	59317386	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	52227004	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15843532	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16873512	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company outsources the manufacture of HOTSHOT to a single co-packer that produces bottled finished goods. The Company also sources certain raw materials from sole suppliers. A disruption in the supply of materials or the production of finished goods could significantly impact the Company's revenues in the future as alternative sources of raw materials and co-packing may not be available at commercially reasonable rates or within a reasonably short period of time. </font></div></div>
CY2017Q1	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Discounts provided to customers are accounted for as a reduction of net product revenue. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to clinical study accruals, estimates related to inventory realizability, stock-based compensation expense and amounts of expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001615219-17-000032-index-headers.html	Edgar Link	pending
0001615219-17-000032-index.html	Edgar Link	pending
0001615219-17-000032.txt	Edgar Link	pending
0001615219-17-000032-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20170331.xml	Edgar Link	completed
flks-20170331.xsd	Edgar Link	pending
flks-20170331_cal.xml	Edgar Link	unprocessable
flks-20170331_def.xml	Edgar Link	unprocessable
flks-20170331_lab.xml	Edgar Link	unprocessable
flks-20170331_pre.xml	Edgar Link	unprocessable
flks201733110-q.htm	Edgar Link	pending
flks2017331ex-311.htm	Edgar Link	pending
flks2017331ex-312.htm	Edgar Link	pending
flks2017331ex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q2 Form 10-Q Financial Statement

#000161521917000032 Filed on May 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2017 Q2 Form 10-Q Financial Statement

#000161521917000032 Filed on May 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx